- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06242470
A Study of MGC026 in Participants With Advanced Solid Tumors
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study.
Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.
Study Overview
Status
Conditions
- Melanoma
- Sarcoma
- Clear Cell Renal Cell Carcinoma
- Cervical Cancer
- Hepatocellular Carcinoma
- Gastric Cancer
- Colorectal Cancer
- Non Small Cell Lung Cancer
- Metastatic Cancer
- Squamous Cell Carcinoma of Head and Neck
- Bladder Cancer
- Advanced Solid Tumor
- Endometrial Cancer
- Small-cell Lung Cancer
- Advanced Cancer
- Platinum-resistant Ovarian Cancer
- Pancreas Cancer
- Gastro-esophageal Cancer
- Castration Resistant Prostatic Cancer
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Global Trial Manager
- Phone Number: 301-251-5172
- Email: info@macrogenics.com
Study Locations
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- Recruiting
- START Midwest
-
-
Utah
-
West Valley City, Utah, United States, 84119
- Recruiting
- START Mountain Region
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults ≥ 18 years old, able to provide informed consent
- Adequate performance and laboratory parameters
- Unresectable, locally advanced or metastatic solid tumors including: squamous cell cancer (SCC) of the head and neck, esophageal SCC, squamous and non-squamous non-small cell lung cancer, small cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, castration resistant prostate cancer, breast cancer, ovarian cancer, cervical cancer, colorectal cancer gastric or gastroesophageal cancer, pancreatic carcinoma, clear cell renal cell cancer or hepatocellular cancer.
- Measurable disease per RECIST v1.1. Participants with metastatic CRPC without measurable disease are eligible.
- Must be willing to use highly effective methods of birth control from the time of consent through 7 months after discontinuation of MGC026.
- Not pregnant or breastfeeding.
Exclusion Criteria:
- Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
- Another cancer that required treatment within the past 2 years, with the exception of those with low risk of cancer spreading or death such as adequately treated non melanomatous skin cancer, localized prostate cancer (Gleason Score < 6), or carcinoma in situ.
- Patients with history of prior central nervous system (CNS) metastasis must have been treated, be asymptomatic, and not have concurrent treatment for CNS disease, progression of CNS metastases on magnetic resonance imaging, computed tomography or positron emission tomography, or history of leptomeningeal disease or cord compression at the time of enrollment.
- Treatment with surgery, systemic cancer therapy, immunotherapy, chimeric antigen receptor-T therapy, or anti-hormonal within protocol specified intervals.
- Prior autologous or allogeneic stem cell or solid organ transplant.
- Clinically significant cardiovascular, pulmonary, or gastrointestinal disorders.
- Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 1 week of first study drug administration.
- Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction.
- Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
- History of primary immunodeficiency.
- Major trauma or major surgery within 4 weeks of first study drug administration.
- Known hypersensitivity to recombinant proteins.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
|
Escalating doses of MGC026
|
Experimental: Cohort 2
|
Escalating doses of MGC026
|
Experimental: Cohort 3
|
Escalating doses of MGC026
|
Experimental: Cohort 4
|
Escalating doses of MGC026
|
Experimental: Cohort 5
|
Escalating doses of MGC026
|
Experimental: Cohort 6
|
Escalating doses of MGC026
|
Experimental: Expansion cohort 1
|
MGC026 recommended dose for expansion
|
Experimental: Expansion cohort 2
|
MGC026 recommended dose for expansion
|
Experimental: Expansion cohort 3
|
MGC026 recommended dose for expansion
|
Experimental: Expansion cohort 4
|
MGC026 recommended dose for expansion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events (AEs) and serious AEs (SAEs)
Time Frame: Throughout the study, up to 135 weeks
|
Throughout the study, up to 135 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate in advanced solid tumors
Time Frame: Throughout the study, up to 135 weeks
|
The objective response rate (ORR) per RECIST v1.1 is estimated as the proportion of participants in the Response Evaluable population who achieve best overall response of complete response (CR) or partial response (PR) (called responders).
Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) is used to classify responses.
|
Throughout the study, up to 135 weeks
|
Duration of response (DoR) in advanced solid tumors
Time Frame: Throughout the study, up to 135 weeks
|
DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented progression or death from any cause, whichever occurs first.
(RECIST 1.1) is used to classify responses.
|
Throughout the study, up to 135 weeks
|
ORR rate in metastatic castration resistant prostate cancer (mCRPC)
Time Frame: Throughout the study, up to 135 weeks
|
The ORR per Prostate Cancer Working Group 3 (PCWG3) criteria is estimated as the proportion of participants in the Response Evaluable population who achieve best overall response of CR or PR (called responders).
|
Throughout the study, up to 135 weeks
|
DoR in mCRPC
Time Frame: Throughout the study, up to 135 weeks
|
DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented progression, per PCWG3 criteria or death from any cause, whichever occurs first.
|
Throughout the study, up to 135 weeks
|
Mean (standard deviation [SD]) of MGC026 maximum serum concentration (Cmax)
Time Frame: Day 1 of every 21-day cycle, throughout the study, average of 1 year.
|
The maximum concentration in the bloodstream at the end of the infusion.
|
Day 1 of every 21-day cycle, throughout the study, average of 1 year.
|
Mean (SD) of MGC026 area under the time concentration curve (AUC)
Time Frame: Day 1 of every 21-day cycle, throughout the study, average of 1 year.
|
Calculated exposure to MGC026
|
Day 1 of every 21-day cycle, throughout the study, average of 1 year.
|
Number of participants who develop anti-MGC026 antibodies (immunogenicity)
Time Frame: Day 1 of every 21-day cycle, throughout the study, average of 1 year.
|
Development of anti-MGC026 antibodies in the bloodstream
|
Day 1 of every 21-day cycle, throughout the study, average of 1 year.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Denise Casey, MD, MacroGenics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Genital Neoplasms, Male
- Prostatic Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Head and Neck Neoplasms
- Kidney Neoplasms
- Pancreatic Diseases
- Carcinoma, Squamous Cell
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Genital Diseases, Female
- Carcinoma, Renal Cell
- Prostatic Neoplasms
- Lung Neoplasms
- Carcinoma
- Endometrial Neoplasms
- Small Cell Lung Carcinoma
- Pancreatic Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Prostatic Neoplasms, Castration-Resistant
Other Study ID Numbers
- CP-MGC026-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
Clinical Trials on MGC026 Dose Escalation
-
Weill Medical College of Cornell UniversityActive, not recruiting
-
Cliniques universitaires Saint-Luc- Université...UnknownHead and Neck CancerBelgium
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
National Cancer Institute, EgyptRecruitingHead and Neck CancerEgypt
-
University Hospital OlomoucUniversity Hospital Ostrava; Masaryk Memorial Cancer InstituteRecruitingHypoxia | Head and Neck Cancer | Dose Escalation | FMISOCzechia
-
Royal North Shore HospitalRecruitingPalliative RadiotherapyAustralia
-
Hinova Pharmaceuticals Inc.RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Hinova Pharmaceuticals Aus Pty LtdCompletedMetastatic Castration-resistant Prostate CancerAustralia
-
Universitaire Ziekenhuizen KU LeuvenUniversity Hospital, GhentCompleted
-
Istituto Clinico HumanitasRecruitingNon Small Cell Lung Cancer | Lung MetastasesItaly